Surgery is the most effective option to treat lung cancer in people with less severe idiopathic pulmonary fibrosis (IPF), a Korean study has found. For IPF patients who have a poorer prognosis (more advanced GAP stages), researchers recommend accounting for cancer clinical stage and estimated tolerability…
Surgery for Lung Cancer Gives IPF Patients Better Prognosis, Study Finds
Esbriet (pirfenidone) shows similar benefits for people with idiopathic pulmonary fibrosis (IPF) in real-world settings as it does in clinical trials, a new study shows. “Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis” was published in the journal…
I feel vulnerable writing about this topic, but if this column opens the door for conversation, my discomfort will be worth it. I recently had a conversation with one of my colleagues about having kids. She is healthy, but I am living with a terminal lung disease called idiopathic pulmonary…
The Pulmonary Fibrosis Foundation (PFF) and Three Lakes Partners are joining forces in the fight against pulmonary fibrosis (PF), according to an announcement to mark National Pulmonary Fibrosis Awareness Month in September. Three Lakes Partners will provide funding to PFF to help the foundation reach its goals of…
My name is Michael Morale. As director of multichannel content for Bionews Services, my job is to bring engaging multimedia content to all of our rare disease communities. I would like to introduce some of the resources available to our Pulmonary Fibrosis News forum members, as well…
Before my mom had a double-lung transplant, my dad was her only caregiver. Holly, my mom, was reasonably independent until a couple of months before being admitted to the ICU. Ed, my dad, was her companion and helper, encouraging her to walk for exercise and helping her…
Processa Pharmaceuticals will explore and further develop the anti-fibrotic, anti-inflammatory compound HT-100 as a potential treatment for rare fibrotic-related diseases in adults, including focal segmental glomerulosclerosis, scleroderma, and idiopathic pulmonary fibrosis (IPF). The company announced that it has acquired the exclusive global rights to develop…
I often write about living with idiopathic pulmonary fibrosis (IPF) and what I’ve lost as a result of my diagnosis. It’s easy to write about because my life has changed drastically over the past three years. But I need to remember that the changes haven’t been all bad.
Protein on Surface of Immune Cells May Drive Inflammation in Pulmonary Fibrosis, Study Suggests
Immune cells can sense the mechanical forces at work in the lungs via a gate called PIEZO1, and deleting this gene in immune cells led to worse lung infections, researchers report. But its loss eased the inflammation associated with lung scarring in a mouse model of pulmonary fibrosis. Their study…
GDF15 Protein May Serve as Biomarker for Identifying IPF Patients with Poor Outcomes, Study Suggests
A protein called GDF15, which is secreted by a type of lung cells, is increased in the lungs and blood of people with idiopathic pulmonary fibrosis, a study shows. Supported by this finding, researchers believe that GDF15 may serve as a biomarker to help identify people who have…
Your PF Community
Recent Posts
- Starting the year with a vision of wellness and a plan to follow through January 15, 2026
- New trial data show oral therapy alters immune pathways in adults with IPF January 14, 2026
- When you’re an IPF patient, the costs of care add up, but help is out there January 13, 2026
- Appearances can be deceptive for those living with pulmonary fibrosis January 13, 2026
- Gut bacteria B. adolescentis may be new preventive treatment for PF January 7, 2026
